We recently published 10 Big Names Delivering Outsized Gains. Viking Therapeutics Inc. (NASDAQ:VKTX) was one of the top ...

After our trades hit some rough waters to end the year in 2025, our swing trading strategy required some adjustments. When ...

Viking Holdings (NYSE: VIK) underwent analysis by 11 analysts in the last quarter, revealing a spectrum of viewpoints from ...

Viking Therapeutics, Inc. (NASDAQ:VKTX) is one of the stocks Jim Cramer discussed, along with recent market rotation. When a ...

The paper, titled, "Weekly Subcutaneous VK2735, a GIP/GLP-1 Receptor Dual Agonist, for Weight Management: Phase 2, Randomized, 13-Week VENTURE Study," was published in Obesity, the peer-reviewed ...

Viking Therapeutics remains a compelling obesity drugs contender, despite being in the pre-commercial phase. VKTX's dual-track pipeline (injectable and oral) and robust $700M liquidity position it ...

Viking Therapeutics, Inc.'s VK2735 oral trial met efficacy and safety endpoints, but high discontinuation rates and modest weight loss disappointed Wall Street, triggering a steep sell-off. Despite ...

Viking, which is also developing a weight-loss pill, has a buy rating from all 13 analysts offering coverage Viking Therapeutics Inc. on Wednesday reported positive data from an early-stage trial of a ...

Investors with a lot of money to spend have taken a bullish stance on Viking Therapeutics (NASDAQ:VKTX). And retail traders should know. We noticed this today when the positions showed up on publicly ...

Stock Snapshot After Recent Moves Viking Therapeutics (VKTX) shares recently caught investor attention after a period of mixed returns, with the stock roughly flat over the past 3 months but showing ...

Unlock your investing potential with TipRanks Premium - Now At 40% OFF! Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter Viking Mines Limited has announced ...